Neurocrine Biosciences

What Neurocrine Biosciences does

Neurocrine Biosciences (NASDAQ: NBIX) is a San Diego-headquartered, neuroscience-focused biopharmaceutical company founded in 1992 that develops and commercializes therapies for neurological, psychiatric, endocrine, and rare diseases. Its commercial portfolio comprises three FDA-approved products: INGREZZA (valbenazine), a selective VMAT2 inhibitor and market leader for tardive dyskinesia and chorea in Huntington's disease; CRENESSITY (crinecerfont), a CRF1 receptor antagonist approved December 2024 as adjunctive therapy for classic congenital adrenal hyperplasia; and VYKAT XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, acquired through the $2.9 billion Soleno Therapeutics deal that closed in May 2026. The company also owns UK subsidiary Diurnal Group (acquired 2022), adding ALKINDI and EFMODY hormone therapies. The pipeline includes the Phase 1 obesity candidate NBIP-2118 (CRF2 agonist) and the Phase 2 schizophrenia candidate NBI-1117570 (dual M1/M4 muscarinic agonist, partnered with Nxera Pharma), with additional late-stage CNS programs in major depressive disorder.

The business model is sales-led specialty pharmaceutical: a U.S. field force targets neurologists, psychiatrists, and endocrinologists through physician detailing, medical science liaisons, and key opinion leader engagement, with products dispensed via specialty pharmacy distribution. Revenue is generated from prescription sales reimbursed by payers, supported by co-pay assistance and patient support programs. Q1 2026 net product sales reached $811 million (+44% YoY), driven by INGREZZA ($656.9M, +20% YoY), CRENESSITY ($153M), and the recently consolidated VYKAT XR. The company employs 1,001–5,000 staff, is publicly traded with approximately 92.6% institutional ownership, and is valued at roughly $16.5 billion as of mid-2026.

Name

Neurocrine Biosciences

Legal name

Neurocrine Biosciences, Inc.

Website

https://neurocrine.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Neurocrine Biosciences is a San Diego-based biopharmaceutical company developing and commercializing FDA-approved neuroscience and endocrinology therapies — including INGREZZA for tardive dyskinesia, CRENESSITY for congenital adrenal hyperplasia, and VYKAT XR for Prader-Willi syndrome — sold through specialty pharmacies to specialist prescribers in the U.S.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)

Keywords

• Specialty pharmaceuticals
• Neurological therapeutics
• Endocrine disorder treatments
• Neuroscience drug development
• Central nervous system drugs

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Product Sales - INGREZZA (valbenazine): INGREZZA generated $656.9 million in net sales in Q1 2026, up 20% year-over-year. The company reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion. INGREZZA is prescribed for tardive dyskinesia and chorea in Huntington's disease. Revenue is generated through specialty pharmacy distribution and payer reimbursements.
2. Product Sales - CRENESSITY (crinecerfont): CRENESSITY generated $153 million in Q1 2026, annualizing above $600 million. FDA approved in December 2024 for classic congenital adrenal hyperplasia in adults and children 4 years and older. Revenue is generated through specialty pharmacy distribution, payer reimbursements, and patient assistance programs.
3. Product Sales - VYKAT XR (diazoxide choline): VYKAT XR generated $190 million in revenue in 2025 following its FDA approval in March 2025. Acquired by Neurocrine through the $2.9 billion acquisition of Soleno Therapeutics in 2026. Prescribed for hyperphagia in Prader-Willi syndrome. Revenue generated through specialty pharmacy distribution and payer reimbursements.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes FDA-approved prescription drugs for neurological, psychiatric, endocrine, and immunological disorders. Its commercial portfolio includes INGREZZA (valbenazine) for tardive dyskinesia, CRENESSITY (crinecerfont) for congenital adrenal hyperplasia, VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome, and ALKINDI/EFMODY hormone therapies from its Diurnal subsidiary, distributed through U.S. specialty pharmacies.

Product overview

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with three FDA-approved commercial products: INGREZZA (valbenazine) for tardive dyskinesia, CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia, and VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome (acquired May 2026). The company also acquired Diurnal Group (UK) adding hormone therapies ALKINDI and EFMODY. The pipeline includes NBIP-2118 (Phase 1, obesity) and NBI-1117570 (Phase 2, schizophrenia). Revenue in Q1 2026 reached $811 million, driven by INGREZZA ($657M) and CRENESSITY ($153M).

Differentiator

Problem solved

Functional benefit

Brands

• INGREZZA: Valbenazine capsules for treatment of tardive dyskinesia
• CRENESSITY
• VYKAT XR
• Diurnal

Products and services

• INGREZZA (valbenazine) INGREZZA is a selective VMAT2 inhibitor capsule prescribed for adults with tardive dyskinesia and chorea associated with Huntington's disease. It is the market-leading TD therapy with $656.9 million in net sales in Q1 2026 (up 20% YoY) and full-year 2026 guidance of $2.7-$2.8 billion. Distributed via U.S. specialty pharmacy partners.
• CRENESSITY (crinecerfont) CRENESSITY is a selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist approved as adjunct treatment for classic congenital adrenal hyperplasia, enabling reduction of supraphysiologic glucocorticoid dosing. Generated $153 million in Q1 2026, annualizing above $600 million.
• VYKAT XR (diazoxide choline) VYKAT XR is the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, an ultra-rare genetic disorder. Acquired via the May 2026 Soleno Therapeutics acquisition; generated $190 million in 2025 revenue with patent protection extending into the 2040s.
• ALKINDI / ALKINDI SPRINKLE (hydrocortisone) ALKINDI and ALKINDI SPRINKLE are registered trademarks of Diurnal Ltd, a wholly-owned Neurocrine subsidiary, providing pediatric hydrocortisone formulations for cortisol deficiency.
• EFMODY EFMODY is a registered trademark of Diurnal Ltd, a wholly-owned Neurocrine subsidiary, marketed as a hormone therapy for cortisol deficiency disorders.

Quantifiable outcome

• 94% of TD patients achieved symptomatic remission or clinically meaningful response (≥30% AIMS score reduction) at 48 weeks with INGREZZA
• +8 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Nxera Pharma (formerly Vitra-Biotech)coreStrategic or Co-development Partner · 12 April 2026Nxera Pharma partnered with Neurocrine Biosciences for the Phase 2 development of NBI-1117570, a dual muscarinic M1/M4 receptor agonist for adults with schizophrenia. Neurocrine dosed the first patient in April 2026, triggering a $22.5 million milestone payment to Nxera Pharma. The Phase 2 study is a double-blind, placebo-controlled trial enrolling approximately 120 patients with primary endpoint of change from baseline in PANSS total score.
• Soleno TherapeuticscoreStrategic or Co-development Partner · 6 April 2026Neurocrine Biosciences acquired Soleno Therapeutics for $2.9 billion in cash ($53 per share, 34% premium), making Soleno a wholly owned subsidiary. The acquisition added VYKAT XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, approved March 26, 2025. The deal closed in May 2026 with approximately 88.9% of Soleno's shares tendered. Soleno had generated $190 million in VYKAT XR revenue in 2025.
• Diurnal Group plcminorStrategic or Co-development Partner · 30 August 2022Neurocrine Biosciences completed the acquisition of Diurnal Group plc, a UK-based hormone therapy company, for approximately £48.3 million (~$57 million) in August 2022. Diurnal developed treatments for disorders such as cortisol deficiency, including ALKINDI, ALKINDI SPRINKLE, and EFMODY. The acquisition expanded Neurocrine's presence in the UK and its endocrinology portfolio. Diurnal became a wholly-owned subsidiary of Neurocrine.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Axsome Therapeutics: Axsome is a CNS-focused biopharma commercializing Auvelity for major depressive disorder and migraine therapies. Comparable as a CNS specialty pharma with newly launched products going through rapid commercial ramp, similar in growth profile and prescriber targets.
• Corcept Therapeutics: Corcept is a specialty pharma with a leading Cushing's syndrome franchise (Korlym) plus a CNS pipeline including treatments for schizophrenia. Comparable in endocrinology/CNS crossover focus, specialty commercial model, and small-cap specialty pharma profile.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biopharma commercializing therapies for genetic and metabolic disorders. Comparable in rare-disease focus, specialty distribution model, and therapeutic areas overlapping with CRENESSITY (CAH) and VYKAT XR (PWS).

Direct peers

• Jazz Pharmaceuticals: Jazz is a specialty biopharma with leading CNS/neurology franchises (Xywav/Xyrem for narcolepsy, Epidiolex for epilepsy) and rare-disease presence. Comparable in specialty sales force model, prescriber focus on neurologists, and growth from both in-line and acquired assets.
• H. Lundbeck: Lundbeck is a global CNS specialty pharma focused on neurology and psychiatry, marketing products for depression, migraine, and movement disorders. Comparable in CNS focus, specialty distribution model, and commitment to neurological/psychiatric indications.
• Teva Pharmaceutical Industries: Teva markets AUSTEDO/AUSTEDO XR, the only direct head-to-head competitor to Neurocrine's INGREZZA in the tardive dyskinesia and Huntington's disease chorea markets. Both companies compete for the same specialty prescriber base (neurologists, psychiatrists) and payer formulary positioning.
• Acadia Pharmaceuticals: Acadia is a CNS specialty biopharma commercializing NUPLAZID (pimavanserin) for Parkinson's disease psychosis and is developing a CNS pipeline including trofinetide. Comparable in size, therapeutic focus (CNS specialty), and rare/neuro indications to Neurocrine.
• Supernus Pharmaceuticals: Supernus is a CNS specialty pharma commercializing treatments for epilepsy, Parkinson's disease, and ADHD through a specialty sales force. Comparable in size, CNS therapeutic focus, and specialty pharmacy distribution model to Neurocrine.
• BioMarin Pharmaceutical: BioMarin is a rare-disease specialty biopharma with multiple first-in-class products (Vimizim, Naglazyme, Voxzogo) targeting small patient populations. Comparable in rare-disease commercial model, specialty distribution, and willingness to pay premium valuations for differentiated assets like VYKAT XR.

Broad incumbents

• Recordati: Recordati is a European specialty pharma with rare-disease (Recordati Rare Diseases) and CNS franchises. Comparable in rare-disease specialty focus, endocrinology presence, and CNS specialty sales motion across multiple geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/i/flow/login?redirect_after_login=%2Fneurocrine
• YouTubeyoutube.com/@NeurocrineBiosciencesInc
• Facebookfacebook.com/Neurocrine
• LinkedInlinkedin.com/company/neurocrine-biosciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurocrine Biosciences